Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a debilitating condition characterized by a marked increase in heart rate upon standing and associated orthostatic symptoms, with no FDA-approved treatments available A single dose of baloncibart reduced the exaggerated heart rate response to standing and improved orthostatic symptoms through four weeks; biomarker changes were consistent with plasma v

Acquired NeuroAirmid Therapeutics, Inc. and Its Cell Therapy Product Candidate for Huntington’s Disease, Currently Enrolling in a Phase 1b/2a Clinical Trial (REGEN4HD) Announced Issuance of a Patent Covering its AlloSCOPE™ “5D” Technology, a Component of Its AlloSCOPE Cell Manufacturing Platform Advanced Collaboration with William Demant Invest for ReSonance ® Into a Second Year; Danish Medicines Agency Meeting Scheduled in Q4 2026 to Discuss Development Plans Advanced Corneal Endothelial Dis

R&D Products For Print November 13, 2026 TOKYO and CAMBRIDGE, Mass., November 13, 2026 — Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that “LEQEMBI® Pen”, the subcutaneous (SC) formulation of “LEQEMBI®” (generic name: lecanemab) has been launched in Japan. LEQEMBI Pen was approved as a new route of administration in Japan on September 16, 2026, and was published in Japan’s National Health Insurance (NHI) Drug Price List today. Following the United States, Japan is the second co

iStock, LvNL Regeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027. A single dose of Regeneron Pharmaceuticals’ investigational monoclonal antibody reduced orthostatic heart rate at eight days for patients with a common autonomic nervous system disorder that causes abnormal heart rate elevations when standing. Regeneron’s Phase 2 Pinnacle trial enrolled 82 patients with postural orthostatic tac

iStock, Leigh Ann Speake ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persistence on treatment. From Nov. 14 through 17, some of the country’s leading weight loss experts and biopharma companies with metabolic assets will gather in Washington, DC, for this year’s ObesityWeek , the annual scientific congress run by The Obesity Society. “Heading into Ob

Primary efficacy endpoint achieved based on preliminary results from a November 5 th data evaluation Topline results for the completed study, along with additional study details including statistical analysis of the primary endpoint, are expected by mid-December 2026 REDWOOD CITY, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form

European Commission to make final decision on arimoclomol MAA following negative CHMP opinion BOSTON, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company committed to redefining what's possible in bringing life-changing therapeutics to people living with rare diseases, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on

- FDA feedback expected in Q4 2026 on proposed use of new formulation of brilaroxazine in the RECOVER-2 trial and a future NDA submission - - U.S. patent office has granted priority examination (Track 1) for the composition of matter patent application filed covering new formulation of brilaroxazine, with potential to extend patent protection through 2046 – - Patient enrollment in RECOVER-2 registrational Phase 3 trial expected to begin in 1H 2027, subject to additional financing – CUPERTINO, C

As reported in its Form 10-Q for the latest quarter, the Company maintains more than $17 million in cash with total assets over $36 million LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) today provided an update on its financial position. As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended July 31, 2026 (PMCB’s fiscal year ends April 30), PharmaCyte held total assets of approximately $36.7 million, including appro

New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families Findings further support investigational ZORYVE cream 0.05% to help address unmet needs in infants aged 3 to <24 months 60% of children develop atopic dermatitis symptoms within their first year of life WESTLAKE VILLAGE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a c